Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders

Author(s): Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti

Apixaban is a new oral selective factor Xa inhibitor. Its efficacy and safety are being investigated in a large clinical development program across various indications in venous and arterial thrombotic disorders. A twice-daily regimen was chosen for all the studied indications of apixaban. All three Phase III studies in the prevention of venous thromboembolism after total hip or knee replacement (ADVANCE-1, -2 and -3) have been completed. On the basis of the data obtained so far, apixaban appears to be a promising new drug for the management of thrombotic diseases.